Moderna (MRNA) Stock Price, News & Analysis

Company Overview

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts. Its products and development programs serve markets in the United States and internationally.

Key Stats

• Today's Range: $250.49 to $273.00
• 50-Day Range: $135.61 to $269.00
• 52-Week Range: $22.28 to $280.80
• Volume: 11.12 million shs
• Average Volume: 12.64 million shs
• Market Capitalization: $100.14 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $113.75
• Consensus Rating: Hold

Moderna Stock Analysis - MarketRank™

Moderna scored higher than 37% of companies evaluated by MarketBeat, and ranked 675th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Moderna has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on no strong buy ratings, 6 buy ratings, 15 hold ratings, and 4 sell ratings.

Downside Risk

Moderna has a consensus price target of $113.75, representing about 54.8% downside from its current price of $251.72.

Amount of Analyst Coverage

Moderna has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moderna are expected to grow in the coming year, from ($6.11) to ($4.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Moderna is -35.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Moderna is -35.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Moderna has a P/B Ratio of 11.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.16% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 1.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moderna has recently increased by 5.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moderna does not currently pay a dividend.

Dividend Growth

Moderna does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.65

News Sentiment

Moderna has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 81 news articles for Moderna this week, compared to 9 articles on an average week.

Search Interest

76 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

45 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,875,904.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/06/2026
• Today: 11/10/2026
• Investor Day 2026: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MRNA
• CIK: 1682852
• Web: www.modernatx.com
• Phone: (617) 714-6500
• Fax: N/A
• Employees: 4,700
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Moderna: $113.75
• High Price Target: $305.00
• Low Price Target: $17.00
• Potential Upside/Downside: -54.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.08
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.82 billion
• Net Margins: -141.43%
• Pretax Margin: -138.55%
• Return on Equity: -28.30%
• Return on Assets: -19.39%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 2.29
• Quick Ratio: 2.18

Sales & Book Value

• Annual Sales: $1.94 billion
• Price / Sales: 51.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.14 per share
• Price / Book: 11.33

Miscellaneous

• Outstanding Shares: 399,240,000
• Free Float: 356,119,000
• Market Cap: $100.14 billion
• Optionable: Optionable
• Beta: 1.16